Citizens analyst Reni Benjamin downgraded Immutep (IMMP) to Market Perform from Outperform without a price target The firm cites the discontinuation of the company’s lead program for the downgrade. The analyst expects the shares to trade inline with the market until randomized study results are reported.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMP:
- Immutep Doubles Half-Year Loss as R&D Spend Rises Despite New Dr. Reddy’s Funding
- Immutep initiated with an Outperform at Citizens
- Immutep Reaches 50% Enrolment in Global Phase III Lung Cancer Trial
- Immutep achieves 50% enrollment in global TACTI-004 Phase III trial
- Immutep Secures Dr. Reddy’s Licensing Deal and Reports Strong Q2 FY26 Clinical and Cash Progress